Consensus: 2005 The toxicities, inconvenience and cost of IP therapy are justified by the improved survival seen with this treatment
New, targeted therapies are likely to be more effective in patients who have an excellent response to chemotherapy
While we work to improve the tolerability and toxicities of IP therapy, it remains the most effective means of treating ovarian cancer today